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ABSTRACT
Objective: To estimate the prevalence and associated risk factors of extended-spectrum β-lactamase producing Enterobacte-
riaceae (ESBL) in King Khaled General Hospital, Saudi Arabia.
Methods: A twelve -month retrospective study for the presence of ESBL producing Enterobacteriaceae infection was per-
formed by using the Microbiology and Infection Control Departments’ database. For all the collected specimens, microbiologi-
cal identification and antimicrobial sensitivity testing were done using MicroScan WalkAway system and then confirmed by API 
20E and E-test respectively.
Results: The prevalence of ESBL producing Enterobacteriaceae infection among studied patients was 22%. The most common 
types of infections were urinary tract infections representing 59.2%. Previous use of antibiotics, urinary catheter, mechanical 
ventilation, previous hospitalization, previous intensive care unit admission and nosocomial origin of infection were significant 
risk factors for acquiring infection. Amikacin had the highest activity against ESBL producing isolates, whereas 20% of isolates 
were resistant to carbapenems 
Conclusions: The study revealed that prevalence of ESBL producing Enterobacteriaceae infection was relatively high. Our 
findings suggest that invasive devices, the use of antibiotics, prolonged hospitalization especially in the intensive care unit in-
creases the risk of acquiring such infections. A strict antibiotic policy should be addressed especially with observed emergence 
of carbapenem resistance. Continuous review of need to invasive devices and strict compliance with basic infection control 
measures are mandatory to limit the spread of ESBL Enterobacteriaceae. J Microbiol Infect Dis 2014; 4(2): 50-54
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Suudi Arabistan’da bir genel hastanede genişlemiş spektrumlu β-laktamaz üreten 
Enterobacteriaceae prevalansı ve risk faktörleri
ÖZET
Amaç: Suudi Arabistan Kral Halid Hastanesi’nde genişlemiş spektrumlu β-laktamaz (GSBL) üreten Enterobacteriaceae prevalan-
sı ve enfeksiyon gelişmesinde risk faktörlerinin belirlenmesi 
Yöntemler: Mikrobiyoloji ve Enfeksiyon Kontrol Birimleri’nin veri tabanı kullanılarak 12 aylık dönemde geriye yönelik olarak 
GSBL üreten Enterobacteriaceae ile enfeksiyon görülme oranı belirlendi. Bu sürede içerisinde elde edilen örneklerde mikrobi-
yolojik tanımlama ve antibiyogram testleri MicroScan WalkAway sistemi kullanılarak yapıldı. Sonuçlar API 20E ve E-test yöntemi 
ile doğrulandı. 
Bulgular: Çalışmaya alınan hastalarda GSBL üreten Enterobacteriaceae prevelansı % 22 olarak bulundu. En sık karşılaşılan en-
feksiyon % 59,2 ile üriner sistem enfeksiyonu idi. Antibiyotik kullanımı, üriner kateterizasyon, mekanik ventilasyon, daha önce 
hastanede yatış, yoğun bakım ünitesinde tedavi görme ve enfeksiyonun hastane kaynaklı olması GSBL üreten Enterobacteria-
ceae ile enfeksiyon gelişmesi için risk faktörleri olarak bulundu. GSBL üreten bakterlere karşı en etkin antibiyotik amikasinken, 
izolatların % 20’sinde karbapenemlere karşı direnç saptandı. 
Sonuçlar: Bu çalışmanın sonuçları GSBL üreten Enterobacteriaceae oranının yüksek olduğunu göstermektedir. Bulgular; anti-
biyotik kullanımı, invaziv işlemler ve özellikle yoğun bakım ünitesine olmak üzere uzamış hastane yatışının GSBL üreten bakte-
rilerle enfeksiyon gelişme riskini artırdığını göstermektedir. Gözlenen yüksek karbapenem direnç oranı antibiyotik kullanımıyla 
ilgili etkin politikalar oluşturulması gerektiğini ortaya koymaktadır. GSBL üreten Enterobacteriaceae yayılmasının engellenmesi 
için kullanılan invaziv cihazlara ihtiyacın sürekli olarak değerlendirilmesi ve temel enfeksiyon kontrol önlemlerine etkin şekilde 
uyulması gerekmektedir. 
Anahtar kelimeler: Enterobacteriaceae, genişlemiş spektrumlu β-laktamaz, prevalans. GSBL, dirençli bakteri, risk faktörleriKandeel A., ESBL epidemiology in a Saudi hospital 51
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INTRODUCTION
In the last twenty years, antimicrobial resistance es-
pecially extended-spectrum β-lactamases (ESBLs) 
have spread among Enterobacteriaceae, particul-
larly Escherichia coli and Klebsiella pneumoniae.1 
Β-lactamases are enzymes that hydrolysis β-lactam 
ring thus destroying the activity of β lactam antibiot-
ics. ESBLs were discovered in 1983 and they can 
hydrolyze  oxyimino-cephalosporins,  and  mono-
bactams, but not cephamycins or carbapenems.2 
ESBLs  together  with  resistance  to  other  antibiot-
ics such as chloramphenicol, trimethoprim, tetra-
cyclines, sulphonamides and aminoglycosides are 
encoded by genes present on large plasmids.3 Ma-
jority of ESBL associated infections are resistant to 
various antibiotics, leaving only limited compounds 
as a therapy.4 Presently, carbapenems became the 
first line antimicrobials for the treatment of such in-
fections.1 The spread of ESBLs has certain conse-
quences such as hindering effective treatment, poor 
outcomes, prolonged hospitalization and increase 
treatment costs.5 Risk factors for ESBLs associated 
infections include patients’ prior comorbidities (such 
as diabetes mellitus, renal failure, immunosuppres-
sion, neoplastic diseases, etc.), long hospital stay, 
advanced age, use of mechanical interventions 
(urinary catheters, venous catheters, endotracheal 
tubes) and previous therapy with broad spectrum 
antimicrobials.6  The  prevalence  of  ESBLs  differs 
between countries and hospitals. In Saudi Arabia 
the prevalence of ESBLs varies greatly in different 
regions. It was shown to be 11% in eastern prov-
ince whereas, in Abha (southern region) and Riyadh 
(central region) it was reported to be 27.5% and 
36%  respectively.7-9 This study was conducted to 
describe the prevalence of ESBLs among Entero-
bacteriaceae in our hospital over a period of one 
year and to identify risk factors for infections. 
METHODS
The current study was conducted in King Khaled 
General  Hospital  (KKGH),  Saudi Arabia  between 
January and December 2012. KKGH is a 300-bed 
tertiary care facility with approximately 23,000 ad-
missions per year. Microbiological results were re-
viewed retrospectively. Only positive cultures for 
Enterobacteriaceae in different specimens from in-
patients were included. If two similar cultures from 
the same patient were encountered, only one was 
included. For analysis, we defined cases as those 
patients with isolates classified as ESBL producers, 
and controls as patients with isolates negative for 
ESBL production. For each patient, age, sex, pre-
vious hospitalization (last six months) or intensive 
care unit admission, nosocomial infection (any in-
fection presented within 48 hours of admission and 
was not diagnosed at that time),10 use of invasive 
devices (more than 48 hours) during current hospital 
stay and previous antibiotic use (more than seven 
days) were recorded from infection control surveil-
lance data. Type of specimen, species of bacteria 
and antibiotic sensitivity pattern were also recorded.
Microbiological methods
The identification of Enterobacteracae species, an-
tibiotic sensitivity testing and ESBL production were 
done by MicroScan WalkAway 96 (Siemens, Sac-
ramento, USA) with its panels (negative breakpoint 
combo42). Results were interpreted by Microscan 
software program, following Clinical and laboratory 
Standards Institute (CLSI) guidelines.11 Confirmtion 
of species identification and ESBL production were 
done  by  API  20E  (bioMerieux,  France)  and  two 
ESBL E test strips for ceftazidime and cefotaxime 
with and without clavulanate (AB Biodisk, Sweden) 
respectively. ESBL diagnosis was considered if MIC 
was reduced by ≥3 twofold dilutions with clavulanic 
acid.
Statistical analysis
The analysis was done using the statistical software 
Open  Epi  (Open  Source  Epidemiologic  Statistics 
for Public Health) Version 3.01. The qualitative data 
were presented in the form of number and percent-
age. Two by two tables are used to evaluate the as-
sociation between a possible risk factor (Exposure) 
and an outcome (Disease). The risk was estimated 
using odds ratio, 95% confidence interval and Chi-
Square. Statistical value of p <0.05 was considered 
to be significant.
RESULTS
A  total  of  1870  patients  with  Enterobacteriaceae 
isolates were included in the study. Out of these, 
412 (22 %) were ESBL producers. The mean age 
of the case group (± standard deviation) was 53.7 
± 17.5years, and (54.6%) of them were male. The 
mean age of the control group (± standard devia-
tion) was 55.3 ± 16.9 years, and (53.4%) of them 
were  male.  E  coli  had  the  highest  prevalence 
(61.2%) followed by Klebsiella pneumonia (22.8%) 
as demonstrated in Table 1.
The distribution of ESBL-producing Enterobac-
teriaceae in different type of specimens is shown 
in Table 2. The clinical characteristics and possible Kandeel A., ESBL epidemiology in a Saudi hospital 52
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risk factors for ESBLs related infections are demon-
strated in Table 3 and the sensitivity rates of ESBL 
producing  Enterobacteriaceae to antibiotics are 
demonstrated in Figure 1.
Figure1.  Antimicrobial  Susceptibility 
rates of ESBL Producing Enterobacte-
riaceae.
Table 1. Distribution of ESBLs isolates according to spe-
cies
ESBL producing species n (%)
Esherichia coli 252 (61.2)
Klebsiella pneumoniae 94 (22.8)
Enterobacter aerogenes 25 (6.1)
Enterobacter cloacae 21 (5.1)
Klebsiella oxytoca 9 (2.2)
Proteus mirabilis 9 (2.2)
Citrobacter spp. 2 (0.4)
Total 412 (100)
Table 2. Distribution of ESBL producing isolates accord-
ing to type of the specimen
Clinical Specimen ESBL producers (%)
Urine 244 (59.2)
Blood culture 28 (6.8)
Others 52 (12.6)
Wound swab 72 (17.5)
Sputum  16 (3.9)
Total 412 (100)
Table 3. Clinical features and potential risk factors for ESBLs producing Enterobacteriaceae infections
Risk factors No. of ESBL (%)
(n=412)
Non-ESBL
(n=1458)
OR
(95% CI)
p value
Male gender 225 (54.6) 778 (53.4) 1.05 (0.84-1.3) 0.35
Old age (≥65 years) 208 (50.4) 760(52) 0.94 (0.75-1.17) 0.3
Nosocomial origin of infection 277 (67) 900(62) 1.27 (1.0-1.60) 0.024
Indwelling urinary catheter 298 (72) 976(67) 1.29 (1.01-1.64) 0.022
Central venous catheter 242 (58.7) 798(54.7) 1.18 (0.94-1.47) 0.083
Mechanical ventilation 139 (33.7) 354(24.3) 1.59 (1.25- 2.01) 0.0001
Previous antibiotic use 378 (92) 1278(88) 1.6 (1.07-2.30) 0.01
Cephalosporins 324 (79) 1069(73) 1.34 (1.03-1.74) 0.02
Fluoroquinolones 182 (44) 546(37) 1.32 (1.06-1.65) 0.01
Recent operation 185 (44.9) 683(46.8) 0.92 (0.74-1.15) 0.26
Previous hospitalization (B6 months) 282 (68.4) 878(60.2) 1.43 (1.14-1.81) 0.001
Previous ICU admission 217 (52.7) 694(47.6) 1.22 (0.99-1.53) 0.04
OR: odds ratio, CI: confidence interval Kandeel A., ESBL epidemiology in a Saudi hospital 53
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DISCUSSION
The rate of ESBLs in bacterial species differs great-
ly all over the world, and rapidly changing from time 
to time.12 The prevalence of ESBLs was reported to 
be over 10% in east Europe, 3.5% in a Canadian 
study and 20-48.8% in Asia.13-15 Within the Arabian 
Gulf region, ESBL prevalence ranged from a low of 
7.5% in Kuwait to as high as 41% in United Arab 
Emirates.16,17 In Saudi Arabia ESBL detection was 
reported to be 27.5% in K. pneumoniae and 36% in 
Enterobacteriaceae. In other studies, It was 15.8% 
and 8.9% in blood cultures and urinary isolates, re-
spectively.7-9,18 In our study the prevalence of ESBL 
was (22%)in Enterobacteriaceae. When compared 
to regional and international data, the ESBL preva-
lence in our institution tends to be towards the high-
er limit. This can be attributed to availability of broad 
spectrum antibiotics, the haphazard use of many 
of them with lack of strict antibiotic policy to con-
trol their use. Their spread cannot be prevented due 
improper isolation of patients with ESBL producing 
strains.
ESBL-producing E. coli is of concern as an im-
portant community-acquired pathogen. Community 
acquired ESBL associated infections are mostly uri-
nary tract infections (UTIs), however some patients 
suffer from intra-abdominal infections and bactere-
mia.1 In Our study (33%) of ESBL associated infec-
tions were acquired within two days of admission. 
Similarly, Ben Ami et al. showed that the prevalence 
of community acquired ESBL associated infections 
was 34.6%.19 On the other hand, in a study con-
ducted in the eastern region of Saudi Arabia, only 
37.9% of the bacteremia due to ESBL producing iso-
lates were hospital acquired.20 Also, in a nationwide 
study conducted in Spain, 51% of ESBL-producing 
E. coli strains were isolated from outpatients.21
In our study E coli had the highest prevalence 
(61.2%)  among  ESBL  producers  followed  by  K. 
pneumoniae (22.8%) and most ESBL isolates were 
detected in urine samples (59.2%).The same find-
ings were observed in other studies and explained 
by the fact that hospitalized patients suffer frequent-
ly from UTIs, and Enterobacteriaceae  (mainly  E. 
coli) are the most common isolated organisms in 
these infections.6,19,22,23 In our study, amikacin was 
quite active against ESBL isolates, which was re-
ported also by Rubio-Perez et al. and attributed it 
to the reduction of aminoglycosides usage to avoid 
renal toxicity.6
In the current study high level of carbapenem 
(20%) resistance has been observed among ESBL 
isolates.  Carbapenems  are  the  first  line  of  treat-
ment of these organisms and, until recently, car-
bapenems resistance was rare among Enterobac-
teriaceae.24 Carbapenem resistance can be due to 
production of carbapenemases, the poor binding of 
carbapenems to penicillin-binding proteins present 
in the bacteria, the over-expression of multidrug ef-
flux pumps by the bacteria or lack of porins in the 
bacterial  cell  membrane.A  combination  of  resis-
tance mechanisms can result with a significant rate 
of resistance.25 In our facility the high rate of car-
bapenem resistance could have been predisposed 
by the wide use of carbapenems as empirical treat-
ment because its broad spectrum, activity against 
ESBL isolates and relatively less side effects com-
pared to amikacin.
Based on our results, antibiotics useage par-
ticularly cephalosporins and fluoroquinolones were 
significantly associated with ESBL associated infec-
tions. Antimicrobial exposure is considered to be an 
important risk factor for ESBL related infections as 
it allows resistant mutants to become the dominant 
strains.26-28 Cephalosporin and fluoroquinolone ex-
posure was reported as risk factor for multidrug re-
sistant bacteria infections, previously.28-30
In our study although central venous catheter 
was not considered as risk factor for ESBL produc-
ing Enterobacteriaceae infections, mechanical ven-
tilation and urinary catheter were both considered 
as risk factors. Similar findings were reported by 
other studies.15,19,29
Previous  hospitalization,  and  nosocomial  ori-
gin  of  infection  were  significantly  associated  with 
ESBL acquisition which was described by other au-
thors.19,26 On the other hand, old age, male gender, 
and recent operation were not significantly associ-
ated with ESBL producing Enterobacteriaceae in-
fections in our study.
Our study has limitations. As noted, high rate 
of carbapenem resistance has been observed but 
since it was a retrospective study, the exact rate 
and mechanism of this resistance could not be con-
firmed.
In conclusion, this study suggests there is a 
high prevalence of ESBL associated infections in 
our setting, which can be attributed to prolonged 
un-reviewed invasive interventions, unrestricted 
use of antibiotics, prolonged and probably unnec-
essary hospital stay. These isolates pose a special 
therapeutic challenge especially with the growing 
resistance to carbapenems. Therefore, strict anti-
biotic policy, continuous review of the need to in-Kandeel A., ESBL epidemiology in a Saudi hospital 54
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vasive devices, minimizing duration of hospital stay 
together with strict compliance to infection control 
precautions would serve as the most efficient way of 
preventing the spread of these organisms. We also 
recommend that carbapenem resistance should be 
thoroughly investigated by further research to know 
the magnitude and mechanism of such resistance. 
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